Literature DB >> 24366206

Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma.

Dong Wang1, Liang Luo2, Wei Chen3, Lian-Zhou Chen4, Wen-Tao Zeng4, Wen Li4, Xiao-Hui Huang4.   

Abstract

The aim of the present study was to investigate the expression of vascular endothelial growth factor (VEGF) and macrophage migration inhibitory factor (MIF) in HCC progression and their correlation with clinicopathological factors as well as the relationship between their expression levels. The expression of serum VEGF and MIF was evaluated in 150 patients with HCC and in 30 normal volunteers by enzyme-linked immunosorbent assay (ELISA). VEGF and MIF expression levels were evaluated by immunohistochemistry on tissue microarrays containing 150 HCCs with paired adjacent non-cancer liver tissues. VEGF and MIF mRNA levels were determined by quantitative PCR in another 48 HCCs. The correlation of VEGF and MIF with clinicopathological factors was analyzed in HCC. Serum VEGF and MIF concentrations were higher in HCC patients than the levels in the controls. The expression levels of VEGF and MIF in the HCC tissues were both higher than those in the adjacent non-tumor liver tissues. Overexpression of VEGF and MIF was significantly associated with tumor size (P=0.027 and 0.022, respectively), intrahepatic metastasis (P=0.032 and 0.027, respectively), vascular invasion (P=0.044 and 0.039, respectively) and TNM stage (P=0.028 and 0.013, respectively). Furthermore, VEGF and MIF mRNA levels were higher in HCC compared to levels in the paired non-cancer liver tissues. VEGF and MIF mRNA levels were correlated with tumor stage and metastasis. The expression of VEGF was positively related with MIF expression in HCC. The expression of MIF and VEGF in HCC was markedly positively correlated, which suggests that MIF and VEGF play an important role in the progression of HCC. Both factors may concomitantly accelerate the progression of HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366206     DOI: 10.3892/or.2013.2946

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Lin Liu; Shukui Qin; Yinghui Zheng; Li Han; Minmin Zhang; Nuo Luo; Zhengcao Liu; Ning Gu; Xiaoyi Gu; Xiaojin Yin
Journal:  Cancer Biol Ther       Date:  2017-02-10       Impact factor: 4.742

3.  Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets.

Authors:  Nadège Kindt; Fabrice Journe; Guy Laurent; Sven Saussez
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

4.  microRNA-451 inhibited cell proliferation, migration and invasion through regulation of MIF in renal cell carcinoma.

Authors:  Yan Tang; Wei Wan; Lijuan Wang; Shishun Ji; Juanjuan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 5.  The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma.

Authors:  Kang Liu; Xu-Li Min; Juan Peng; Ke Yang; Lin Yang; Xiao-Ming Zhang
Journal:  J Clin Med Res       Date:  2016-02-27

Review 6.  Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach.

Authors:  Katia Mangano; Emanuela Mazzon; Maria Sofia Basile; Roberto Di Marco; Placido Bramanti; Santa Mammana; Maria Cristina Petralia; Paolo Fagone; Ferdinando Nicoletti
Journal:  Oncotarget       Date:  2018-04-03

7.  MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma.

Authors:  Lifeng Qin; Jinmei Qin; Xiaoping Lv; Caiqiao Yin; Qian'e Zhang; Jiqiao Zhang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

Review 8.  Macrophage migration inhibitory factor involvement in breast cancer (Review).

Authors:  Vincent Richard; Nadège Kindt; Sven Saussez
Journal:  Int J Oncol       Date:  2015-09-24       Impact factor: 5.650

9.  Macrophage-tumor cell fusions from peripheral blood of melanoma patients.

Authors:  Gary A Clawson; Gail L Matters; Ping Xin; Yuka Imamura-Kawasawa; Zhen Du; Diane M Thiboutot; Klaus F Helm; Rogerio I Neves; Thomas Abraham
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

10.  Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation.

Authors:  Xiao-Hui Huang; Wei-Hua Jian; Zhao-Feng Wu; Jie Zhao; Hua Wang; Wen Li; Jin-Tang Xia
Journal:  Oncotarget       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.